More than 152,000 new cases of NMSC are diagnosed every year – more than breast, prostate and lung cancers combined
News
Bayer’s finerenone hits targets in diabetes/kidney disease trial
The drug hit primary and secondary goals of the Phase III FIDELIO-DKD renal outcomes study
Research journals commit to action on equality
Joint commitment led by the Royal Society of Chemistry, which has created a framework to reduce bias and discrimination that it is hoped ‘will help reshape journals all over the world’
US priority review for AZ’ Brilinta/aspirin combination
Brilinta/aspirin combo could be the first US-approved dual antiplatelet therapy to cut risk of second stroke
Charity warns of ‘catastrophic’ effect of COVID-19 on stroke research
UK’s leading stroke charity warns research faces long-term threat due to coronavirus pandemic
NICE backing for Takeda’s Adcetris for rare lymphoma
Standard of care in untreated systemic anaplastic large cell lymphoma (sALCL) has not changed in several decades
CMA levies fines of £2.3m in pharma probe
The fines are in addition to £8 million secured for the NHS last year as part of the case
US rejects MSD/Eisai’s Keytruda Lenvima combo
Regulators rejected accelerated approval as Roche’s combination for the same patient population made it over the line first
UK researchers back use of steroid inhalers during pandemic
The benefit outweighs the risks for asthma and COPD patients during the pandemic, they say
Gilead begins PhI trial of inhaled remdesivir
The inhaled formulation is being assessed for COVID-19 patients in the outpatient setting
Final data on ViiV’s cabotegravir show impressive HIV PrEP
The long-acting, injectable therapy was 66% more effective than daily oral tablets at preventing HIV
New clinical trial platform launched to accelerate COVID-19 treatments
AGILE is a ‘proof of confidence engine’ designed to quickly identify the most promising compounds for treatment of COVID-19
GSK links with Medicago to develop novel COVID-19 vaccine
Phase I clinical testing scheduled to begin mid-July
EU nod for Lynparza in pancreatic cancer
The drug is the only PARP inhibitor approved in this disease
Regeneron kicks off Phase III trial of COVID-19 antibody cocktail
This follows a positive review from the Independent Data Monitoring Committee of REGN-COV2 Phase I safety results
